Key Clinical Message
Treatment of mCRPC resistant to ARATs is a clinical challenge. Docetaxel
could significantly improve the survival of these patients. However,
when resistance to taxane-based chemotherapy develops, treatment options
are limited. Administration of supraphysiological doses of testosterone
might re-sensitize cancer cells to various treatment modalities
including hormonal and chemotherapy.